Results 101 to 110 of about 63,206 (209)

Primary CNS Lymphoma Presenting With Seizures in a Virologically Suppressed HIV Patient With Near‐Normal CD4: A Case Report From Uganda

Clinical Case Reports, Volume 14, Issue 4, April 2026.
Brain MRI of a 40‐year‐old virologically suppressed HIV patient with primary CNS lymphoma. ABSTRACT We report a case of primary central nervous system lymphoma (PCNSL) in a 40‐year‐old man with well‐controlled HIV infection, virologic suppression, and a near‐normal CD4 count who presented with new‐onset generalized seizures and left lower motor neuron ...
Abdisalam Ahmed Sandeyl, Abdisamad Guled Hersi, David Elia Saria, Farah Dubad Abdi, Venance Emmanuel Mswelo, Sura Daniel Elias, Elias Amare Hailu, Hailemariam Kassahun Bekele   +7 more
wiley   +1 more source

Acute kidney injury KDIGO stage 2 to 3 in HIV-positive patients treated with cART – a case series over 11 years in a cohort of 1,153 patients

Swiss Medical Weekly, 2015
OBJECTIVES: We aimed to explore acute kidney injury (AKI) Kidney Disease Improving Global Guidelines (KDIGO) stage 2 to 3 in a cohort of antiretroviral treated HIV-infected individuals.
Mario Kurz, Felix Burkhalter, Michael Dickenmann, Helmut Hopfer, Michael Mayr, Luigia Elzi, Manuel Battegay   +6 more
doaj   +1 more source

Risk of Acute Kidney Injury Associated With Nephrotoxic Burden in Hospitalized Patients: A Scoping Review

Clinical Pharmacology &Therapeutics, Volume 119, Issue 4, Page 891-904, April 2026.
Limited evidence exists synthesizing the risk of acute kidney injury (AKI) associated with the concomitant administration of multiple nephrotoxic drugs, and even less examining the concept of nephrotoxic burden. The objective of this scoping review was to (1) identify definitions of nephrotoxic burden; (2) methods used to quantify (use of calculations)
Wafa Alatawi, Jessica L. Wallace, Dhakrit Rungkitwattanakul, Britney A. Stottlemyer, Tiffany L. Tran, Melanie Manis Reida, Sandra L. Kane‐Gill   +6 more
wiley   +1 more source

Progress towards the elimination of vertical transmission of HIV, syphilis and hepatitis B in 21 high‐burden countries

Journal of the International AIDS Society, Volume 29, Issue 4, April 2026.
Abstract Introduction Elimination of mother‐to‐child transmission (EMTCT) of HIV, syphilis and hepatitis B by 2030 is a global goal endorsed by countries. To achieve EMTCT, countries need to meet targets for programme and impact indicators. Methods We examined progress and gaps in service delivery across the three infections among 21 countries with a ...
Melanie M. Taylor, Rania A. Tohme, Robert McDonald, Michele Montandon   +3 more
wiley   +1 more source

Is there Emergence of Clinical HBV Resistance Under Long-Term HBV Combination Therapy? A Challenging Case Report

Viruses, 2010
A first case of clinical tenofovir (TDF) HBV resistance in an HIV/HBV coinfected patient who developed an acute flare of hepatitis B is reported. The clinical course was accompanied by signs of acute liver failure after being on successful HBV treatment ...
Jürgen Kurt Rockstroh, Jan van Lunzen, Stefan Schmiedel, Hüseyin Sirma, Christian Noah, Knud Schewe, Oliver Schildgen   +6 more
doaj   +1 more source

Persistent risk for new, subsequent new and recurrent hepatocellular carcinoma despite successful anti-hepatitis B virus therapy and tumor ablation: The need for hepatitis B virus cure. [PDF]

, 2019
Hepatitis B virus (HBV) is one of the most significant hepatocarcinogens. The ultimate goal of anti-HBV treatment is to prevent the development of hepatocellular carcinoma (HCC).
Coben, Robert M., Conn, Mitchell I., DiMarino, Anthony J., Hann, Hie-Won, Kroop, Howard, Martin, Aaron, Prieto, Jorge, Shinn, Brianna J.   +7 more
core   +1 more source

Hepatitis B Virus RNA Predicts Hepatocellular Carcinoma Despite Viral Suppression

Alimentary Pharmacology &Therapeutics, Volume 63, Issue 8, Page 1089-1098, April 2026.
Serum HBV RNA levels at viral suppression predict HCC development in nucleos(t)ide analogue‐treated patients with chronic hepatitis B, outperforming Hepatitis B core‐related antigen alone. ABSTRACT Background Despite achieving undetectable hepatitis B virus (HBV) DNA levels with nucleos(t)ide analogue (NA) therapy, patients with chronic hepatitis B ...
Takashi Kumada, Hidenori Toyoda, Satoshi Yasuda, Yuichi Koshiyama, Takanori Ito, Tomoyuki Akita, Junko Tanaka   +6 more
wiley   +1 more source

Unsuccessful therapy with adefovir and entecavir-tenofovir in a patient with chronic hepatitis B infection with previous resistance to lamivudine: a fourteen-year evolution of hepatitis B virus mutations

BMC Infectious Diseases, 2011
Background Complex mutants can be selected under sequential selective pressure by HBV therapy. To determine hepatitis B virus genomic evolution during antiviral therapy we characterized the HBV quasi-species in a patient who did no respond to therapy ...
Tanno Hugo, Fay Fabian, Benetti Silvina, Cassino Lucila, Quarleri Jorge   +4 more
doaj   +1 more source

HBV RNA Predicts the Risk of Off‐Treatment Relapse in Chronic Hepatitis B Patients With NAs Therapy: A Systematic Review and Meta‐Analysis

Journal of Viral Hepatitis, Volume 33, Issue 4, April 2026.
ABSTRACT Since there are currently few antiviral drugs that can effectively reduce hepatitis B surface antigen levels, the recurrence rate remains high in patients with chronic hepatitis B (CHB) after discontinuing nucleoside analogues (NAs) treatment.
Dong‐Hui Wang, Jia‐Lan Wang, Su‐Wen Jiang, Ai‐Wu Zhou, Meng‐Han Jin, Hao‐Jin Zhang, Shi‐Qi Yang, Shi‐Yang Fan, Ai‐Rong Hu   +8 more
wiley   +1 more source

Vaccines at the Heart of Hepatitis Elimination: Insights From the ESCMID Study Group for Viral Hepatitis (ESGVH)

Liver International, Volume 46, Issue 4, April 2026.
ABSTRACT The global elimination of viral hepatitis by 2030 remains an ambitious goal that hinges not only on diagnostics and therapeutics but fundamentally on the strategic use and continued innovation of vaccines. The ESCMID Study Group for Viral Hepatitis (ESGVH) convened to examine the role of vaccination as the cornerstone of hepatitis prevention ...
Oana Săndulescu, Gülşen Özkaya Şahin, Susanne Gjeruldsen Dudman, Zeinab Nabil Ahmed Said, Mario U. Mondelli, on behalf of ESCMID Study Group for Viral Hepatitis (ESGVH)   +5 more
wiley   +1 more source